Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 88

Sort by

Sort Order Select

Journal Articles

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Blood (2018) 132 (Supplement 1): 790.

https://doi.org/10.1182/blood-2018-99-116803

Published: 2018

Journal Articles

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Michael Byrne, MD, Mark G. Frattini, MD PhD, Oliver G. Ottmann, MD, Ioannis Mantzaris, MD MS, Martin Wermke, MD, Daniel J. Lee, MD, Daniel Morillo, MD, Arne Scholz, PhD, Stuart Ince, PhD, Ray Valencia, MD, Fabricio Souza, MD, Raul Cordoba, MD PhD

Blood (2018) 132 (Supplement 1): 4055.

https://doi.org/10.1182/blood-2018-99-117257

Published: 2018

Journal Articles

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

Claudia Chiriches, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt

Blood (2018) 132 (Supplement 1): 3917.

https://doi.org/10.1182/blood-2018-99-116631

Published: 2018

Journal Articles

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Michelle Lazenby, BSc, Oliver G. Ottmann, MD, Keith Wilson, FRCPath, MRCP, MBBS, Caroline Alvares, MBBS, PhD, Joanna Zabkiewicz, PhD

Blood (2018) 132 (Supplement 1): 2744.

https://doi.org/10.1182/blood-2018-99-113342

Published: 2018

Journal Articles

Adipogeneis in the Bone Marrow Microenvironment Confers a Proliferative Advantage in Residual Leukaemic Cell Populations in Acute Myeloid Leukaemia after Allogeneic Stem Cell Transplantation

Felicity May, BSc, Caroline Alvares, MBBS, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD

Blood (2018) 132 (Supplement 1): 2580.

https://doi.org/10.1182/blood-2018-99-114443

Published: 2018

Journal Articles

Bone Marrow Stromal Cells Mediate Adhesion Based Drug Resistance in Acute Myeloid Leukaemia through Reciprocal Feedback of the β-Catenin/CD44 Signalling Axis

Lihui Zhuang, PhD MSc, BSc, Richard Darley, PhD, Oliver G. Ottmann, MD, Joanna Zabkiewicz, PhD, Caroline Alvares, MBBS, PhD

Blood (2018) 132 (Supplement 1): 2776.

https://doi.org/10.1182/blood-2018-99-113811

Published: 2018

Journal Articles

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

Blood (2018) 132 (Supplement 1): 31.

https://doi.org/10.1182/blood-2018-99-114552

Published: 2018

Journal Articles

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

Blood (2017) 130 (Supplement 1): 1414.

https://doi.org/10.1182/blood.V130.Suppl_1.1414.1414

Published: 2017

Journal Articles

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Claudia Chiriches, PhD, Dilawar Khan, PhD, Nathalie Guillen, PhD, Michal Rokicki, Carol Guy, Afsar Mian, PhD, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2016) 128 (22): 2746.

https://doi.org/10.1182/blood.V128.22.2746.2746

Published: 2016

Journal Articles

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Marie Gilmour, PhD, Anna Scholtz, Oliver G. Ottmann, MD, Robert K Hills, DPhil, Steven Knapper, Joanna Zabkiewicz, PhD

Blood (2016) 128 (22): 2754.

https://doi.org/10.1182/blood.V128.22.2754.2754

Published: 2016

Journal Articles

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Monika Haubitz, PhD, Elisabeth Oppliger Leibundgut, PharmD, Ingrid Helsen, Dania Hiltbrunner, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Röth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2016) 128 (22): 1938.

https://doi.org/10.1182/blood.V128.22.1938.1938

Published: 2016

Journal Articles

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

Blood (2016) 128 (22): 625.

https://doi.org/10.1182/blood.V128.22.625.625

Published: 2016

Journal Articles

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Oliver G. Ottmann, MD, Giuliana Alimena, Daniel J. DeAngelo, MD PhD, Yeow-Tee Goh, MBBS, MMed, Michael C. Heinrich, MD, Andreas Hochhaus, MD, Timothy P. Hughes, MD MBBS, FRACP, FRCPA, Francois-Xavier Mahon, MD PhD Professor, Michael J. Mauro, MD, Hironobu Minami, MD D.MDSci., Marie Huong Nguyen, MD, Delphine Rea, Juan Luis Steegmann, MD, Arkendu Chatterjee, Varsha Iyer, Noelia Martinez, Gary J. Vanasse, MD, Kim Dong-Wook, MD PhD

Blood (2015) 126 (23): 138.

https://doi.org/10.1182/blood.V126.23.138.138

Published: 2015

Journal Articles

Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial

Gesine Bug, MD, Andreas Burchert, MD, Eva-Maria Wagner, MD, Nicolaus Kroeger, MD, Zuzana Jedlickova, MD, Saskia Gueller, MD, Stephan Metzelder, MD, Andrea Wolf, Peter Bader, MD, Sabine Huenecke, PhD, Hubert Serve, Oliver G. Ottmann, MD

Blood (2015) 126 (23): 4344.

https://doi.org/10.1182/blood.V126.23.4344.4344

Published: 2015

Journal Articles

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Giovanni Martinelli, MD, Hervé Dombret, Patrice Chevallier, MD PhD, Oliver G. Ottmann, MD, Nicola Goekbuget, MD, Max S. Topp, MD, Adele K. Fielding, MB BS, PhD, Lulu Ren Sterling, PhD, Jonathan Benjamin, MD, Anthony Selwyn Stein, MD

Blood (2015) 126 (23): 679.

https://doi.org/10.1182/blood.V126.23.679.679

Published: 2015

Journal Articles

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Elisabeth Oppliger Leibundgut, PharmD, Monika Haubitz, PhD, Bart Burington, PhD, Oliver G. Ottmann, MD, Gary Spitzer, MD, Olatoyosi Odenike, MD, Michael A McDevitt, MD PhD, Alexander Roeth, MD, David S. Snyder, MD, Gabriela M. Baerlocher, MD

Blood (2015) 126 (23): 57.

https://doi.org/10.1182/blood.V126.23.57.57

Published: 2015

Journal Articles

Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study

Blood (2015) 126 (23): 2861.

https://doi.org/10.1182/blood.V126.23.2861.2861

Published: 2015

Journal Articles

Mechanisms of Antileukemic Activity of the Multikinase Inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) Harboring the E2A-PBX1 Fusion Gene

Tamara Tesanovic, Susanne Badura, Thomas Oellerich, Claudia Doering, Martin Ruthardt, MD, Oliver G. Ottmann, MD

Blood (2014) 124 (21): 3595.

https://doi.org/10.1182/blood.V124.21.3595.3595

Published: 2014

Journal Articles

The GSK3β-Phosphorylation Sites in the DEK-Portion Are Indispensable for the Leukemogenic Potential of the DEK/CAN Fusion Protein in t(6;9)-Positive Acute Myeloid Leukemia

Claudia Oancea, PhD, Maria Heinßmann, Nathalie Guillen, Oliver G. Ottmann, MD, Martin Ruthardt, MD

Blood (2014) 124 (21): 3574.

https://doi.org/10.1182/blood.V124.21.3574.3574

Published: 2014

Journal Articles

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Patrick A. Zweidler-McKay, MDPhD, Daniel J. DeAngelo, MDPhD, Dan Douer, MD, Hervé Dombret, MD, Oliver G. Ottmann, MD, Norbert Vey, MD, Deborah A. Thomas, MD, Lili Zhu, MSc, Fei Huang, PhD, Gaurav Bajaj, PhD, Bruce S. Fischer, MD

Blood (2014) 124 (21): 968.

https://doi.org/10.1182/blood.V124.21.968.968

Published: 2014

NARROW

Phase-1 Study of PF-114 Mesylate in CML Failing Prior Tyrosine Kinase-Inhibitor Therapy

Phase I Study of the PTEFb Inhibitor BAY 1251152 in Patients with Acute Myelogenous Leukemia

Subtractive Interaction Proteomics Reveal a Network of Signaling Pathways Activated By an Oncogenic Transcription Factor in High Risk AML

Extracellular Microvesicle Cytokines Secreted from Bone Marrow Mesenchymal Cells Mediate Proliferative and Survival Advantage in Acute Myeloid Leukaemia

Adipogeneis in the Bone Marrow Microenvironment Confers a Proliferative Advantage in Residual Leukaemic Cell Populations in Acute Myeloid Leukaemia after Allogeneic Stem Cell Transplantation

Bone Marrow Stromal Cells Mediate Adhesion Based Drug Resistance in Acute Myeloid Leukaemia through Reciprocal Feedback of the β-Catenin/CD44 Signalling Axis

Nilotinib (Tasigna ® ) and Low Intensity Chemotherapy for First-Line Treatment of Elderly Patients with BCR-ABL1- Positive Acute Lymphoblastic Leukemia: Final Results of a Prospective Multicenter Trial (EWALL-PH02)

A Knowledge-Based Approach for Clinical Annotation of Oncogenic Variants to Support Patient-Tailored Diagnosis in Myeloid Disease

A Network of Activated Cancer Signaling Pathways in a High Risk Subgroup of Acute Myeloid Leukemia Targetable By SRC-Kinase Inhibitors

Axl/ Mer Inhibitor ONO-9330547 As a Novel Therapeutic Agent in a Stromal Co-Culture Model of Primary Acute Myeloid Leukaemia (AML)

Dynamics of Telomere Length Reflect the Clonal Suppression Seen with the Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia

Expanded Phase 1 Study of ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Reveals Significant and Durable Responses in Patients with CML-Chronic Phase with Failure of Prior TKI Therapy

ABL001, a Potent, Allosteric Inhibitor of BCR-ABL, Exhibits Safety and Promising Single- Agent Activity in a Phase I Study of Patients with CML with Failure of Prior TKI Therapy

Phase I/II Study of the Deacetylase Inhibitor Panobinostat As Maintenance Therapy after an Allogeneic Stem Cell Transplantation in Patients with High-Risk MDS or AML: The Panobest-Trial

Complete Molecular and Hematologic Response in Adult Patients with Relapsed/Refractory (R/R) Philadelphia Chromosome-Positive B-Precursor Acute Lymphoblastic Leukemia (ALL) Following Treatment with Blinatumomab: Results from a Phase 2 Single-Arm, Multicenter Study (ALCANTARA)

Dynamics of Mutations in Patients with ET Treated with Imetelstat

Panobinostat Plus Azacitidine in Adult Patients with MDS, CMML, or AML: Results of a Phase 2b Study

Mechanisms of Antileukemic Activity of the Multikinase Inhibitors Dasatinib and Ponatinib in Acute Lymphoblastic Leukemia (ALL) Harboring the E2A-PBX1 Fusion Gene

The GSK3β-Phosphorylation Sites in the DEK-Portion Are Indispensable for the Leukemogenic Potential of the DEK/CAN Fusion Protein in t(6;9)-Positive Acute Myeloid Leukemia

The Safety and Activity of BMS-906024, a Gamma Secretase Inhibitor (GSI) with Anti-Notch Activity, in Patients with Relapsed T-Cell Acute Lymphoblastic Leukemia (T-ALL): Initial Results of a Phase 1 Trial

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only